Geron: FDA delays 1st trial of stem cell treatment
By AP,
Associated Press
| 08. 17. 2009
Regulators are delaying a trial of an embryonic stem cell treatment for spinal cord injury, drug developer Geron Corp. said Tuesday.
Geron ( GERN - news - people ) said the Food and Drug Administration is reviewing new data from studies of the therapy, called GRNOPC1, on animals. The company plans to start testing its product on humans this summer, but that testing will be delayed during the FDA's review. Geron said it will work with the FDA, and did not estimate how long the review will take.
The product is derived from human embryonic stem cells, and the company says it has tested the drug in 24 separate studies involving rats and mice. The FDA cleared human testing in January, and since then, Geron said it has been studying different doses of the stem cell treatment, and testing it against other neurodegenerative diseases.
The planned trial will involve eight to 10 patients. It plans to recruit patients who recently became paraplegics, meaning they can use their arms but are unable to walk. They will be injected with GRNOPC1 within...
Related Articles
Reproductive rights have been a flashpoint in national politics for decades, with the stakes surging after the Supreme Court shredded the right to an abortion. In the current presidential campaign, the battle over abortion has swelled and morphed to encompass in vitro fertilization (IVF), which has now moved rapidly from widely accepted to partisan hot button.
This dramatic shift was highlighted by the February decision of the Alabama Supreme Court that granted personhood rights to frozen IVF embryos, signaling that...
By Gabby Del Valle, The Baffler | 09.17.2024
IT’S A COMMON STORY, banal, even: a child of privilege, an heir apparent, leaves for college to get a good enough education—and maybe have a little fun—before taking over the family business. But the child, away from the nest for...
By Deirdre Walsh , NPR | 09.17.2024
Senate Republicans blocked a Democratic bill to provide a nationwide right to IVF treatments. It was the second time Senate Democrats tried and failed to advance the measure.
Reproductive freedom has remained a central issue in several Senate contests that...
By Ali Breland, The Atlantic | 08.20.2024
“Joining us now is Steve Sailer, who I find to be incredibly interesting, and one of the most talented noticers,” Charlie Kirk said on his internet show in October. Kirk, the 30-year-old founder of Turning Point USA, a right-wing...